通过前哨淋巴结活检进行精准分期以实现肛门癌个体化治疗。

Refined staging by sentinel lymph node biopsy to individualize therapy in anal cancer.

作者信息

Ulmer Christoph, Bembenek Andreas, Gretschel Stephan, Markwardt Jörn, Koswig Stephan, Schneider Ulrike, Schlag Peter Michael

机构信息

Department of Surgery and Surgical Oncology, University Hospital Charité, Campus Buch, Robert Roessle Klinik at the Helios Klinikum, Berlin, Germany.

出版信息

Ann Surg Oncol. 2004 Mar;11(3 Suppl):259S-62S. doi: 10.1007/BF02523641.

DOI:10.1007/BF02523641

PMID:15023764

Abstract

We evaluated the feasibility of the sentinel lymph node technique to refine staging and potentially individualize therapy for anal cancer. Seventeen patients with cancer of the anal canal underwent peritumoral injection of 99mTc-colloid, followed 17 hours later by lymphoscintigraphy. A selective lymph node biopsy (SLNB) was attempted in 12 of 13 cases with scintigraphically detected SLNs. Lymph node metastases were present in 5 of 12 cases (42%); in 2 of these 5 cases, micrometastases were detected only by immunohistochemical staining. Hence, SLNB refines the diagnostic workup for anal cancer and provides an accurate basis for individualized therapy.

摘要

我们评估了前哨淋巴结技术用于完善肛管癌分期及实现个体化治疗的可行性。17例肛管癌患者接受了瘤周注射99mTc-胶体，17小时后进行淋巴闪烁显像。在13例经闪烁显像检测到前哨淋巴结的患者中，有12例尝试进行了选择性淋巴结活检（SLNB）。12例中有5例（42%）存在淋巴结转移；在这5例中的2例中，仅通过免疫组化染色检测到微转移。因此，SLNB完善了肛管癌的诊断检查，并为个体化治疗提供了准确依据。